Please try another search
PARIS--(BUSINESS WIRE)--Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene...
Growth of 1.2% at constant exchange rates for the third quarter of FY 2023-2024Over 9 months, sales in France up +5.3%.International sales up 8.4% at constant exchange rates over 9 months VALENCE,...
Increase in services provided in 2023 by all sequencing platforms, excluding COVID-related activitiesPositive EBITDA for the third year running, despite inflation impacting reagent costsSeqOIA...
The Kauffman Foundation in a recently published report said that public stock markets have outperformed the average venture capital fund over the last decade. Kauffman is a twenty-year old endowment...
If you've been stuck searching for Mid Cap Growth funds, consider T. Rowe Price Institutional Mid-Cap Equity Growth PMEGX as a possibility. PMEGX possesses a Zacks Mutual Fund Rank of 1 (Strong Buy),...
Note: My text editor was not available, so please excuse any grammar mistakes in this week’s article. Following this market is an exercise in frustration. Last week, the Dow Jones appeared ready...
Instrument Type
Region
Sector
Industry
Date
Category
Provider